amhsr-open access medicla research journals
*Corresponding Author:
Prof. Motamedifar M,
Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Zand St, Imam Hossein Sq, Shiraz, Iran.

Citation: Moghadam MN, Motamedifar M, Sarvari J, Sedigh ESH, Mousavi SM, Moghadam FN. Emergence of multidrug resistance and metallo-beta-lactamase producing Acinetobacter baumannii isolated from patients in Shiraz, Iran. Ann Med Health Sci Res 2016;6:162-7.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.


Background: Metallo‑beta‑lactamase (MβL) enzymes production is one of the most important resistance mechanisms against carbapenems in some bacteria including Acinetobacter baumannii. Aims: This study was aimed to determine the antimicrobial susceptibility and the prevalence of MβL among carbapenem‑resistant isolates of A. baumannii. Materials and Methods: In this cross‑sectional study from October 2012 to April 2013, 98 isolates were identified as A. baumannii using Microgen™ kits and confirmed by molecular method. These isolates were tested for antimicrobial susceptibilities by disk diffusion method according to the Clinical and Laboratory Standards Institute guidelines. Carbapenem‑resistant isolates were further detected phenotypically by MβL minimal inhibitory concentration (MIC)‑test strips, and subsequently positive MβL isolates were confirmed by polymerase chain reaction (PCR). Results: Overall, 98% (96/98) of A. baumannii isolates were detected as carbapenem‑resistant by MIC test. Highest sensitivity to the tested antibiotic with 42.9% (42/98) was observed to colistin. Of 96 carbapenem‑resistant isolates, 43 were phenotypically positive for MβL; out of 43 isolates, 37 were confirmed for the presence of MβL genes by PCR. Conclusion: The frequency of drug resistance among the clinical samples of A. baumannii isolated in our study against most of the antibiotics was very high. Moreover, all MβL producing isolates were multidrug resistance. Therefore, systematic surveillance to detect MβL producing bacteria and rational prescription and use of carbapenems could be helpful to prevent the spread of carbapenem resistance.


Acinetobacter baumannii, Antibiotic resistance, Carbapenem, Iran, Metallo-beta-lactamase


Acinetobacter baumannii is a nonmotile, Gram-negative, nonfermentative, oxidase-negative, and aerobic Bacilli, which is one of the most opportunistic pathogens against human.[1,2] The bacteria are widespread in the environment and are considerably resistant to most antibiotics, low nutrient, and arid condition.[3] Acinetobacter spp. cause a variety of nosocomial infections, but A. baumannii is the prevalent species with high morbidity and mortality, including pneumonia, bacteremia, urinary tract, and skin and soft tissue infections, especially in patients with severe illness.[1,3,4] At the recent years, the continuously increasing prevalence rates of nosocomial infections by multidrug-resistant (MDR) A. baumannii in the Intensive Care Units (ICUs) have led to rise mortalities at the hospitals.[5-7]

A. baumannii has propensity to acquire resistance; a mechanism of this resistance is being characterized by the production of a specific enzyme called metallo-beta-lactamases (MβLs).[4,7] These enzymes belong to Ambler class B beta-lactamases based on their amino acid sequence homology and to Group 3 according to the Bush classification based on their substrate profiles (imipenem hydrolysis).[7] These enzymes are inhibited by ethylenediaminetetraacetic acid (EDTA).[8]

In Iran, several studies have previously been carried out on drug resistance of A. baumannii, revealing a high resistance rate to most of the antibiotics.[9-11] However, a few studies have been conducted in Iran, especially in our region, aiming to find the prevalence of MβL producing genes among clinical isolates of A. baumannii. The aims of the present study were to investigate MDR and determine the prevalence of MβL genes among carbapenem-resistant isolates of A. baumannii from clinical specimens in Shiraz, Southwest of Iran.

Materials and Methods

Sampling and bacterial isolates

In this cross-sectional study from October 2012 to April 2013, 120 Acinetobacter isolates were recovered from clinical specimens. The specimens were randomly collected from patients in different wards of two hospitals, Nemazee and Faghihi in Shiraz, a major city in Southwest of Iran. Nemazee and Faghihi hospitals are the two major tertiary care hospitals with 1000 beds, affiliated to Shiraz University of Medical Science, Shiraz, Iran. Sample size was calculated as about 100 using the formula [12]:


The study was in accordance with declaration of Helsinki; however, because we only used laboratory clinical specimens and did not harm any of the patients, the local ethics committee waived the need for informed consent.

Totally, 98 isolates were identified as A. baumannii isolates using Microgen diagnosis Kits. These 98 isolates were recovered from 35 sputum, 15 wound swab, 13 body fluids, 9 blood, 9 urine, 8 endotracheal tube, 5 cerebrospinal fluid, and 4 other samples (included 2 bronchoalveolar lavage, 1 eye swab, and 1 axillary swab). Overall, 53 samples were collected from ICUs and 45 samples from other wards (included gastroenterology, skin, surgery, and transplant) in the two above-mentioned hospitals. Confirmed isolates were kept at − 70°C until for long preservation.

Antimicrobial susceptibility testing

The susceptibility of the isolates to 16 antibiotics disk (MAST, UK) was investigated using disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) recommendation.[13] The test was performed on Mueller-Hinton agar (Merck, Germany) with followed antibiotics disks containing 10 μg imipenem, 10 μg meropenem, 30 μg amikacin, 10 μg gentamicin, 30 μg aztreonam, 30 μg ceftazidime, 5 μg ciprofloxacin, 5 μg levofloxacin, 100 μg piperacillin, 10 μg tobramycin, 25 μg colistin, 20 μg ampicillin/sulbactam, 10 μg ampicillin, and 110 μg piperacillin/tazobactam. Pseudomonas aeruginosa ATCC 27853 was used as the control strain in susceptibility testing.

Minimal inhibitory concentration

Minimal inhibitory concentration (MIC)-test strips (Liofilchem, Italy), containing imipenem and meropenem, were used to determine the MIC according to the instruction provided by the company on Muller-Hinton agar (Merck, Germany). Results were interpreted using CLSI criteria.

Phenotypic metallo-beta-lactamase detection

MIC-test strip (Liofilchem, Italy), containing imipenem/ imipenem + EDTA, was used to determine the phenotypic MβL enzyme production. MIC-test strip was performed according to the manufacturer’s instructions. A reduction in the MIC of imipenem of ≥ 3 dilutions in the presence of EDTA was interpreted as a positive test. In addition, a strain was considered MβL producer if a phantom zone or deformation of the eclipse was observed.

DNA extraction and molecular typing

The isolates which were intermediately resistant or resistant to imipenem or meropenem were considered carbapenem-resistant. Extraction of genomic DNA from A. baumannii isolates was performed according to the protocol as previously described.[14] Polymerase chain reaction (PCR) assay was performed for the detection of blaOXA-51-like gene, a 353 base-pair (bp) amplicon, as an internal gene for molecular confirmation of A. baumannii isolates at the species level (primer sequence: F/5’-TAA TGC TTT GAT CGG CCT TG-3′, R/5′-TGG ATT GCA CTT CAT CTT GG-3′),[15] and for amplification of MβL encoding genes, blaIMP, blaVIM, and blaSPM using the following consensus primer sets, blaIMP: F/5’-GAA GGC GTT TAT GTT CAT AC-3’, blaIMP: R/5’-GTA TGT TTC AAG AGT GAT GC-3’ which amplify a 587 bp amplicon, blaVIM: F/5’-GTT TGG TCG CAT ATC GCA AC-3’, blaVIM: R/5’-AAT GCG CAG CAC CAG GAT AG-3’ which amplify a 382 bp amplicon,[16] and blaSPM: F/5’-AAA ATC TGG GTA CGC AAA CG-3’, blaSPM: R/5’-ACA TTA TCC GCT GGA ACA GG-3’ which amplify a 271 bp amplicon.[17] A P. aeruginosa harboring blaIMP, blaVIM, blaSPM genes (obtained from Pasteur Institute of Iran) was used as the positive control.[18]

Statistical analysis was performed using SPSS software version 19.0 (IBM Corp., Armonk, NY, USA). The results for infectious agents and antimicrobial susceptibility presented as descriptive statistics in terms of relative frequency. Chi-square or Fisher’s exact test was used to analyze the results wherever they needed. P < 0.05 was considered as statistically significant clinical relevance.


Of 98 A. baumannii isolates, 54.1% (53/98) of isolates were collected from female patients’ samples. Seventy isolates were obtained from Namazee and 28 from Faghihi Hospital. Most of the 98 A. baumannii isolates were recovered from sputum (n = 35), wound swab (n = 15), and body fluids (n = 13).

The highest antibiotic resistance rates were observed against aztreonam, ceftazidime, ciprofloxacin, piperacillin, and cefotaxime since all of the tested isolates showed resistance. In addition, no sensitive isolates were seen against aztreonam and cefotaxime; just a few isolates were in the intermediate level of susceptibility. The results of antibiotic susceptibility patterns for the tested isolates are displayed [Table 1].

Antibiotic disks Total (n=98) n (%)
  Sensitive Intermediate Resistance
Meropenem 3 (3.1) 0 95 (96.9)
Imipenema 4 (4.1) 0 94 (95.9)
Amikacin 24 (24.5) 6 (6.1) 68 (69.4)
Gentamicin 13 (13.3) 11 (11.2) 74 (75.5)
Aztreonam 0 0 98 (100)
Cefoxitin 0 0 98 (100)
Ceftazidime 0 0 98 (100)
Ciprofloxacin 0 0 98 (100)
Levofloxacin 0 0 98 (100)
Piperacillin 0 0 98 (100)
Piperacillin-tazobactam 0 0 98 (100)
Ampicillin 0 0 98 (100)
Ampicillin-sulbactam 5 (5.1) 0 93 (94.9)
Colistin 42 (42.9) 0 56 (57.1)

Table 1: Susceptibility patterns of Acinetobacter baumannii isolates to 16 tested antibiotics by disc diffusion method.

Totally, 98% (96/98) of the isolates were detected as carbapenem-resistant by MIC-test strip. Among the carbapenem-resistant A. baumannii isolates, 44.8% (43/96) were found to be MβL producers by MβL MIC-test strips. Interestingly, the majority 85.7% (84/98) of the isolates showed an MIC ≥ 48 µg/ml. MIC ranges for the tested isolates to imipenem are presented in Table 2. All phenotypically MβL producing isolates were MDR and exhibited high resistance to beta-lactams, aminoglycosides, and fluoroquinolones. Furthermore, three of the MβL producing isolates were sensitive to ampicillin-sulbactam.

MIC (μg/mL)sample Sensitive≤4 μg/mL Resistance≥16 μg/mL
  2 24 32 48 64 98 128 Total number
Sputum 0 1 2 2 10 9 11 35
Wound 1 0 0 2 3 4 5 15
Body fluids 0 1 0 2 1 7 2 13
Urine 0 1 2 1 2 3 0 9
Blood 0 0 1 2 2 4 0 9
ETTa 0 2 1 2 2 1 0 8
CSFb 1 0 1 2 0 1 0 5
Other 0 0 0 2 1 0 1 4
Total number 2 5 7 15 21 29 19 98

Table 2: Distribution of resistance rate of the studied Acinetobacter baumannii isolates to imipenem by E-test based on source of isolation.

Finally from MβL producing isolates, 86% (37/43) were positive for MβL genotypes, of which 53.4% (23/43) isolates carried blaIMP, 32.6% (14/43) carried blaVIM MβL genes, and none of the isolates carried blaSPM gene. PCR results for amplification of MβL producing genes are displayed in Table 3.

MβL gene Sample Place of isolation Total number
IMP-1 Sputum ICU 6
IMP-1 Sputum Gastroenterology 2
IMP-1 Body fluids ICU 2
IMP-1 Wound ICU 2
IMP-1 Wound NICU 1
IMP-1 Wound Transplant 1
IMP-1 Blood ICU 2
IMP-1 Blood Transplant 1
IMP-1 Urine ICU 2
VIM-2 Sputum ICU 2
VIM-2 Sputum Gastroenterology 1
VIM-2 Wound ICU 2
VIM-2 Wound NICU 1
VIM-2 Urine ICU 2
VIM-2 Blood ICU 1
VIM-2 Blood NICU 1
VIM-2 Body fluids ICU 1
VIM-2 ETT Gastroenterology 1
VIM-2 Other NICU 1

Table 3: Distribution of metallo-beta-lactamase genes among the studied Acinetobacter baumannii isolates

From the total ICUs recovered isolates, 47.2% (25/53) carried one of the blaIMP or blaVIM genes; this rate for isolates from other hospital wards was 26.7% (12/45). Despite the higher proportion for blaIMP and blaVIM gene in ICUs compared to other wards, no significant differences were observed (P = 0.06). The frequencies of blaIMP and blaVIM genes for Namazee hospital isolates were 22.9% (16/70) and 12.9% (9/70), respectively. The similar rates for Faghihi Hospital isolates were 25% (7/28) for blaIMP and 17.9% (5/28) for blaVIM genes.


One of the carbapenem resistance mechanisms is production of carbapenem-hydrolyzing β-lactamases, which is called carbapenemase; one of them, MβL is more important in drug resistance against carbapenems.[7,19]

In the recent years, there have been numerous reports on MDR A. baumannii from hospital settings in Iran.[10-11] In most of these studies, only characterized isolates were obtained from ICUs while this study attempted to determine the resistance among isolates obtained from various medical wards as well. In particular, 45 clinical samples were isolated from wards outside ICUs. Antibiotic susceptibility testing showed that the majority of the isolates were resistant to three or more antibiotics [Table 1] while all the isolates were resistant to imipenem, cefotaxime, and ciprofloxacin, and 95% and 96% of the isolates were resistant to meropenem and amikacin, respectively.

Carbapenems are the best choice for nosocomial infections of Acinetobacter in Iran. However, in the recent years, it has been reported that there is reduced susceptibility to imipenem.[10,11,20]

Further, resistance to colistin, polymyxin, and tigecycline which are the usual choices for nosocomial infections of carbapenem-resistance Acinetobacter is increased around the world, especially in Iran.[10,11,21] Our results suggest colistin as the best choice for A. baumannii isolates in-vitro; this is in accordance with the finding of Japoni-Nejad et al. from Arak, Central area of Iran, that reported colistin and tigecycline as the most effective antibiotic agents against A. baumannii isolates.[10]

In a relatively similar study, Feizabadi et al. reported the prevalence of susceptibility of A. baumannii to imipenem, meropenem, piperacillin-tazobactam, and amikacin rate of 50.7%, 50%, 42.1%, and 38.2%, respectively.[22] These rates indicated higher sensitive isolates compared to our rates with 4.1%, 3.1%, 0%, and 24.5%, respectively. Our results showed a higher resistance rate of A. baumannii isolates against most of the studied antibiotics which were almost similar compared to some studies carried out throughout Iran and other countries.[23-25]

In this study, of the 96 (98%) carbapenem-resistant A. baumannii, 44.8% were found to be MβL producers by MIC-test strips. Such a high resistance rate to imipenem is not uncommon since two separate studies by Safari et al. and Noori et al. have previously shown 99% resistance among their tested isolated by MIC-test strips and disk diffusion methods, respectively.[11,21] Abdalhamid et al. from Saudi Arabia, in contrast with Iranian studies, reported lower carbapenem-resistant A. baumannii (46/141; 32.6%); however, MβL was much higher than that of Iranian report since 43 of 46 carbapenem-resistant A. baumannii isolates were MβL positive.[26]

All MβL producing isolates in our study were MDR and exhibited high resistance to beta-lactams, aminoglycosides, and fluoroquinolones. This high rate of MDR in our study was in agreement with a study from our neighboring country, Pakistan, which reported the prevalence of MDR 100% among A. baumannii isolates.[27] Three of our MβL-producing isolates were sensitive to ampicillin-sulbactam.

In the present study, from a total of 43 MβL producing isolates, 86% were positive for MβL genotypes and subsequently 53.4% and 32.6% of the isolates carried blaIMP and blaVIM genes, respectively.

As it is seen in our results, phenotypic and genotypic results of the detection of MβL producing isolates were not the same. Possible reason of higher positive rates for phenotypic MβL production could be the presence of MβL genes other than those we have screened.[28,29]

In a previous Iranian study conducted in Tabriz, from a total of 63 carbapenem-resistant A. baumannii, 31 (49%) were found to be MβL producers by MIC-test strips, of which 19 isolates carried blaIMP and 9 carried blaVIM genes; these rates were remarkably close to our findings.[20] In addition, Noori et al. from the capital of Iran reported a blaIMP-1 gene prevalence of 3 of 86 (3.48%) among MβL A. baumannii isolates.[21]

In the current study, no blaSPM gene was detected among A. baumannii isolates; previously, two similar attempts for detection of blaSPM gene by Shahcheraghi et al. (2009–2010) and Noori et al. (2012–2013) were made in Tehran, Iran; only, Shahcheraghi et al. was able to detect this gene in 6 out of 100 tested A. baumannii isolates.[18,21] Reports about the prevalence of these genes among A. baumannii isolates from other parts of the world have shown different patterns. Abdalhamid et al. from Saudi Arabia and Al-Agamy et al. from Egypt reported negative PCR results for blaIMP, blaVIM, and blaSPM genes among all MβL producing isolates.[26,30] However, previously, blaIMP and blaVIM prevalences have been reported from Greece, China, Korea, and India.[31-34] The present study has some limitations. First, lack of DNA sequencing for knowing the IMP and VIM variants must be mentioned as a limitation of our study. Moreover, employed a typing method could clear the connection between isolates and source of infections in studied hospitals.


The prevalence of drug resistance among the clinical samples of A. baumannii isolated in our study against most of the antibiotics is very high. Hence, early detection and optimization of infection control practices are the best defenses against these organisms. Therefore, systematic surveillance to detect MβL producing bacteria and rational prescription and use of carbapenems could be helpful to prevent the spread of carbapenem resistance.


The authors would like to thank Ms. N. Pirbonyeh and Mr. B. Dehghani for their technical assistance. This study was supported by Shiraz University of Medical Sciences with grant No. 92-6515. This article is extracted from the MSc thesis by M. N. Moghadam under the supervision of Dr. M. Motamedifar.

Financial support and sponsorship

This study was supported by Shiraz University of Medical Sciences with grant No. 92-6515.

Conflicts of interest

There are no conflicts of interest.


Select your language of interest to view the total content in your interested language

Awards Nomination
20+ Million Readerbase
Abstracted/Indexed in

  • Include Baidu Scholar
  • CNKI (China National Knowledge Infrastructure)
  • EBSCO Publishing's Electronic Databases
  • Exlibris – Primo Central
  • Google Scholar
  • Hinari
  • Infotrieve
  • National Science Library
  • ProQuest
  • TdNet
  • African Index Medicus
Annals of Medical and Health Sciences Research The Annals of Medical and Health Sciences Research is a bi-monthly multidisciplinary medical journal.
Submit your Manuscript